SCHEMBL532254

SCHEMBL532254

CON(C)C(=O)[C@H](C)N(Cc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HPGD P15428 1/20 0.48
FAAH O00519 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
ATM Q13315 1/20 0.41
ACHE P22303 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17046806 1.00 MEN1 (0.50) MEN1KMT2AHPGDFAAHALDH1A1
SCHEMBL17046807 1.00 MEN1 (0.50) MEN1KMT2AHPGDFAAHALDH1A1
SCHEMBL1370386 0.89 HPGD (0.49) MEN1KMT2AHPGDFAAHALDH1A1
SCHEMBL1370385 0.89 HPGD (0.49) MEN1KMT2AHPGDFAAHALDH1A1
SCHEMBL24332207 0.89 HPGD (0.49) MEN1KMT2AHPGDFAAHALDH1A1
SCHEMBL2493250 0.84 KMT2A (0.56) MEN1KMT2AHPGDALDH1A1LMNA
SCHEMBL15855790 0.84 KMT2A (0.56) MEN1KMT2AHPGDALDH1A1LMNA
SCHEMBL4310816 0.79 KMT2A (0.51) MEN1KMT2AHPGDALDH1A1LMNA
SCHEMBL19349131 0.79 MEN1 (0.61) MEN1KMT2AHPGDALDH1A1LMNA
SCHEMBL9328469 0.78 HPGD (0.47) MEN1KMT2AHPGDFAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3272749-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma Aktiengesellschaft (DE) 2018-01-24 EP disclosed
EP-2914594-B1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE Bayer Pharma AG (DE) 2017-05-03 EP disclosed
US-9605003-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-03-28 US disclosed
US-20150246932-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2015-09-03 US disclosed
EP-2415759-A1 CETP inhibitors Merck Sharp & Dohme Corporation (US) 2012-02-08 EP disclosed
US-20110178059-A1 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-21 US disclosed
US-7915271-B2 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2011-03-29 US disclosed
US-7910592-B2 CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2011-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246932-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB MEN1 1386/4885KMT2A 3819/4885HPGD 836/4885
US-20110178059-A1 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS CETP, MTTP, APOB MEN1 4049/4885KMT2A 2516/4885HPGD 1595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.